Curis Inc. (NASDAQ:CRIS)
Bands
Volume
200 SMA
50 SMA
20 SMA
Videos
Alerts
Articles
Events
Old Forum Content for CRIS
Make a Forum Post Become a member to view recent forum posts. Already a member? Sign in here.
- lostsheep: $CRIS After a big move and some stabilization the entry was 13.82 2 inside days and up
- Babutters: @gtr89 a couple breakfast burritos. Watching carnage. Also, congrats to anyone in $CRIS.
- Cjauger: $CRIS, thin name, trying to go higher
- Cjauger: Added to $CRIS with a stop on the new shares at the LOD $8.20
- Cjauger: $CRIS this one is should just go, moving all my stops to the LOD
- Cheezit: $cris Day 2 up big . I bought small spec play yesterday.
- ScottT: Opened some new positions in the premarket. $DKNG $PENN $CRIS. all are working. Sold $LAZR on the pop @ open. A LT hold has made a good move this morning on a buy rating. $OTRK is up $4. Still holding $JMIA. working well.
- debeers: $CRIS-on promising leukemia news, HC Wainwright adjusts the price from 5 to 9. uris Early Stage Study Shows Encouraging Clinical Activity with Leukemia Treatment Candidate, Shares Jump 9:15 AM ET, 12/08/2020 - MT Newswires 09:15 AM EST, 12/08/2020 (MT Newswires) -- Curis (CRIS) shares climbed by more than 220% in premarket trading on Tuesday after the biotechnology company said its CA-4948 small molecule has shown encouraging clinical activity in an early stage study of patients with acute myeloid leukemia and myelodysplastic syndromes, or cancers characterized by immature blood cells in the bone marrow. Based on initial data from the ongoing phase 1 study, CA-4948 led to reductions in immature blood cells called marrow blasts, the company said. One patient had blast count going from 23% pretreatment to 1% on treatment, and the other from 11% pretreatment to 2% on treatment. The study aims to determine the maximum tolerated dose and recommended phase 2 dose for CA-4948, the firm said.
- ScottT: @debeers $CRIS Bought some in premarket this morning. Much needed. My neice had non-hodgkins lymphoma. Its tough. Thankfully she went into remission.
- woodman: $CRIS - LOL! I don't know how many days I've looked at this one and said the same thing: "I can't chase this here."
- Tricia: $CRIS Curis Announces Investigational New Drug Application Filing by Roche to Initiate a Phase 2 Study ... http://ow.ly/2IPVW2
- Tim S: Notable earnings before Thursday's open $ACT, $AER, $CBB, $CCO, $CDE, $CONE, $CRIS, $CRY, $CVI, CVRR, $CWEI, $CYBX, @DAN, $DNR, $DTV, $ELOS, $EXAS, $FCN, $FDML, $FUN, $HEP, $HRL, $HSC, $HSNI, I, $ICLR, $ICON, $IDCC, $IMAX, $IRC, $LTM, $LXP, $MRGE, $PAAS, $PDCO, $PEG, $PWR, $RS, $SCG, $SONS, $SUI, $THI, $TK, $TRP, $TTC, $UAN, $UPL, $WLK, $WLT, $WMT, $WWE, YNDX
- :
- woodman: $ARRY - careful, mhh. See $CRIS for a lesson.
- Tim S: Notable earnings before Monday's open $CRIS, $ROC, $TSN, ZINC
- Big D: Quick check on Earnings After the Close, today Wednesday or Before the Open tomorrow, Thursday: $ABC, $ABX, $AFFX, $AHT, $ALKS, $ALL, $ANSS, $APA, $ARIA, $ARQL, $ATK, $AVG, $AXS, $BBG, $BCE, $BLT, $BMC, $BRY, $BYD, $CACI, $CBM, $CBOE, $CCJ, $CEVA, $CI, $CJES, $CLDX, $COHR, $COT, $CRIS, $CTRX, $CVC, $CWH, $CZR, $DRE, $DX, $EEP, $EL, $ELLI, $END, $ENH, $EPD, $ESS, $ESV, $EXAS, $EXH, $EXTR, $FBN, $FCH, $FSLR, G, $GAS, $GBX, $GEO, $GGC, $GGP, $GNK, $GTAT, $GTIV, $GTLS, $GWR, $HEES, $HNSN, $HOS, $HSC, $HSH, $HT, $INCY, $IPI, $IRC, $IRDM, $IVZ, $JKHY, $K, $KEG, $KRA, $KRO, KSWS, $LBTYA, $MD, $MDU, $MET, $MPC, $MRGE, $MTG, $MUR, $NBIX, NGLS, $NIHD, $NPSP, $OCN, $OIS, $PDCE, $PEG, $PES, $PKD, $PMTC, $PVA, $PXD, $PXP, $RGLD, $RGR, $RRD, $SE, $SFY, $SHOO, $SM, $SNE, $SNI, $SPR, $SU, $TDC, $TE, $TEVA, $TMH, $TREX, $UNM, $UPL, $UTHR, $V, $VC, $VICL, $VMC, $VNR, $VNTV, $WNC, $WNR, WPI, $XOM, XYL
- Tricia: CLDX: got some analyst love also - @Boris Peaker, an Executive Director and Senior Analyst at Oppenheimer & Co. Inc.has Celldex Therapeutics (CLDX) as a top pick among the smaller names in the oncology space. He says the company's opportunity in the breast cancer space and the data it is going to present in December may be exciting for the biotech sector - ( Dr. @Slowtime is going to be doing the super happy dance). You can buy his research for $AMGN, $CELG, $CLDX, $IMGN, $CRIS, $PSTI, $CNDO, and PBTH for $75 from the wall street Transcript. I like this analyst's research - both for quality and clarity. gl.
- vroth: $CRIS - target raised BRIEF-RESEARCH ALERT-Roth Capital raises Curis to buy July 8 (Reuters) - Curis Inc : * Roth capital partners raises Curis Inc to buy from neutral; raises price target to $7 from $4.60
- vroth: I own three breakouts from two days ago where there is no profit taking. $WPRT, $SWSH, $CRIS, I noticed $WPRT got substantial new orders and buy recommendation. $SWSH may be on a short #squeeze trip, $CRIS is a small biotech I read about on thestreet.com. I am keeping my stops tight.
- vroth: $CRIS - breakout!
- bullmoose: $CRIS (@vroth) - Thanks for the shoutout, unfortunately I saw it way too late. I would like to have gotten in just as it was surpassing 3.45. Good luck with the trade.
- CallaLilly: Biotech - HGSI belongs on the list along with $VRML (lost its Q). Studying some charts of the participants in the BioCEO Conference next week (February 8-9). Biotech usually moves on good news (or bad). Last week savaged biotech but still ... Some I'm looking at are $CERS, $PPHM, $IMGN, $ACHN, $KERX, $SCLN, $CVM (most think this is pumped), $CHTP, $BMRN (nice, very nice), $OREX,OPXA, $ARIA, $ACAD, $ALKS, ISPH, $RPRX, ALTH, $CRIS, $PDLI, $ACOR ( on fire), $GNVC (good entry), SUPG (still in uptrend), MRNA, $ALNY, $ATHX, $CYTK ... well there's more but this is more than enough to look at pipeline and charts. DDSS as a February 11 FDA date for Trazadone, which is getting a lot of attention.
- CallaLilly: $CRIS - what an explosion ... I wish I had known about it. Up high here and worthy indeed of a serious look. The problem I have with biotechs is understanding completely what they do in relation to their peers and rely heavily on biomedreports.com to detail the stock. Wonderful ...
- Virgil25: Good Morning, I am back, having finished all my preparations for taxes and ready to take up charts against the storm:) I want to wish everyone a happy Easter and a great weekend. Yesterday I took positions in 2 biotechs: ALTH & CYPB. I had held the prior one for a while and CYPB seemed to me a bargain at the current prices so I took a nibble. Here's what I currently own: ALTH, $ARQL, $CORT, $CRIS, CYPB, $ENZN, GTEC, $HALO, IDEV, $IDIX, $IDRA, NTII, OLGC, $OPTR, PCOP, $RGEN, $SGEN, SNTA. I have to get to the dentist but will try to get back with some rationales later in the day. /* @Phil */
- Virgil25: Hello All, Sorry, I forgot about the evening chat. Someone was inquiring earlier re: Biotechs. I'll be happy to respond to any inquiries. I tend to post periodically what I am buying and selling. What I currently hold (read the piece on Biotechs in Tutorials 'On Biotech Investing' for an overview) are the following with length of time held in mos: Time held ..... Gain/Loss % $CORT 2.3 ..... -12% $CRIS 3.7 ..... +36.7% $ENZN 9.69 ..... -9.7% GTEC 2.21 ..... -15% $HALO 14.3 ..... +89% IDEV 5.9 ..... -11.5% $IDIX .33 ..... -2.6% $IDRA 10.4 ..... +22.5% NTII 2.9 ..... +6.8% OLGC 8.9 ..... -33% $OPTR 3.5 ..... -30% PCOP 12.2 ..... -18.9% $RGEN 9.7 ..... +94.84% $SGEN .33 ..... -2.95% SGXP 12 ..... +6% $SNTA 3 ..... +10.78% Average hold period is 6 months, Gain for group is 10.78%. This is what is Currently held. There was a profitable sale and 2 minor losses in 2008 when COLY was bought by PFE. The latter are not reflected in current overal gain of 10.78. as always, /* @Phil */
- Virgil25: Picked up some more $DMLP, $MWA, $IDIX, $CRIS, $SGEN and started a position in SNG that I've owned before. That's it for today. Mueller water is an excellent water products co that I've bought & sold before. $DMLP is a nat gas producer, pays high #dividend (10%+). $IDIX, $CRIS, $SGEN are biotechs that I've been building a position in. SNG is a Canadian oil/gas exploration co that I sold for a profit late '07. /* @Phil */
-
Virgil25: ...
$CRIS -- Sold half of my shs last yr, may buy more. --
$ENZN -- Cancer drugs, Cambridge, Ma
GTEC -- this co originally US, bought by fairly large Chinese co to gain access to US exchanges. Purely speculative play.
$HALO -- "Its Enhanze Technolo ... - Virgil25: Hello Everyone, Been absent for a while as a result of holidays, truck accident (no one injured or hit), and year-end selling & a bit of buying: -- selling all biotech losses most of which I buy back 30 days later since I believe in them and have large gains. -- rebought $BQI -- oil sands quest for 4.19. Sold earlier for profit. -- rebought $AUY --excellent Gold/copper co. " " " " Portfolio now down to manageable 52 positions and will stay in that area:) The following biotech look interesting, though haven't bought yet: $OREX, ARYX, $ETRM, VRUS Current biotech holdings: Coly, Cort, $CRIS, GTEC, $HALO, IDEV, $IDRA, $LXRX, NTII, OLGC, $OPTR, PCOP, $RGEN, SGXP, SNTA. as always, /* @Phil */
- Virgil25: Have a 220% gain since July in COLY which was just bought by Pfizer. In addition, currently holding: AOLS, $ARQL, CNU, $CRIS, GNLB, GTCB, $HALO, IDEV, IDP, JAV, $LXRX, MGIFF, NTII, OLGC, $OPK, $OPTR, $OXGN, PCOP, $RGEN, $SGEN, SGXP, $SNTA, ZIOP. I do not advise anyone buying any of these without reading the piece here under Tutorials/Trading Concepts:'Biotech Investing' as this is a specific area that requires some study. /* @Phil */
- Virgil25: Thanks @Bob, I am working on an outline of how I approach the sector. Have a rough draft which I might post today or tomorrow. Here is what I currently hold: AOLS, $ARQL, CNU, COLY, $CORT, $CRIS, EPIX, GNLB, GTCB, $HALO, IDEV, IDP, JAV, $LXRX, MGIFF, OLGC, $OPK, PCOP, $RGEN, SGXP, TPPH, $ZIOP In terms of investing, it's a different balliwick than almost all the other sectors in that only one of the above -- CNU -- has a PE:( The rest of them are losing money. So you are buying on an entirely different basis -- except for the technicals which are also important in this sector. I will follow up shortly with my current approach but all methods are subject to improvement.:o) /* @Phil */
-
Virgil25: ...
I manage a fairly large group of issues on a daily basis. In biotech I currently hold AOLS, $ARQL, CNU, COLY, $CORT, $CRIS, EPIX, GNLB, GTCB, $HALO, IDEV, IDP, JAV, $LXRX, MGIFF, OLGC, $OPK, PCOP, $RGEN, SGXP, TPPH, AND ZIOP. And there are others I ...
| Stock Price | $15.22 |
| Change | -4.58% |
| Volume | 19,626 |
Curis, Inc., is a drug discovery and development company that is committed to leveraging its innovative signaling pathway drug technologies in seeking to develop next generation targeted cancer therapies.
Request Video of CRISAlready a member? Sign in here.
Past Month
Leading Peers
-
$5.07 259.09%
-
$5.46 129.20%
-
$5.11 79.40%
Past Month
Lagging Peers
-
$15.66 -104.82%
-
$30.02 -79.38%
-
$6.66 -69.76%
Dan Fitzpatrick
Stock Market Mentor gives you EVERYTHING you need to succeed in the market; all in one place. How easy is that? Dan Fitzpatrick and his elite community of traders share trading ideas, strategies and much more. Dan Fitzpatrick--a world class Technical Analyst, trading coach and regular CNBC contributor--gives you access to all of this with a 30 day trial membership for just $7.77. Get started TODAY and start trading better TOMORROW with the following premium content:
- Nightly video Strategy Sessions with a game plan for tomorrow
- Got a stock you want Dan to look at? Just ask.
- Patent pending video alerts instantly delivered to you when one of Dan’s trading signals is triggered. This is not your typical price alert. This is a short video explaining the action you need to take to make money. No more “Woulda, coulda, shoulda”
- Access to over 90,400 stock analysis videos
- Access an ever expanding library (90,400) of educational videos that will save you time and make you money
Join a team of friends and traders that have one thing in common; a burning desire to succeed.
Become a Member Today!
Gain immediate access to all our exclusive articles, features, how-to's, discussion group and much more...
Satisfaction Guaranteed!
Your Stock Market Mentor membership comes with a 30 day, no questions asked, 100% money back guarantee!